App-Quantinova.ai

Optical Coherence Tomography assessment of the implantation of Everolimus-Eluting Bioresorbable Scaffolds against angiographic assessment: the clinical outcomes

Stephen Hamshere - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Clopidogrel bisulfate

One-Year Prognostic Utility of the SYNTAX Score II in Complex PCI with Biodegradable Polymer Drug-Eluting Stents: A PANDA III Analysis

Changdong Guan - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Fluoropassivation of Coronary Stents as a Potential Mechanism of Improved Thromboresistance

Sho Torii - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Everolimus

The Promus Premier everolimus-eluting platinum chromium Stent with durable polymer Evaluated in a real world All-comer population in Rotterdam Cardiology Hospital (the P-SEARCH registry)

Miguel Lemmert - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Venous thrombosis

Everolimus

BIOTRONIK-Safety and Clinical Performance of the Drug Eluting Orsiro Stent in the Treatment of Subjects With Single De Novo Coronary Artery Lesions-II (BIOFLOW-II) 4 Year Clinical Results

ton slagboom - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Venous thrombosis

Everolimus

Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent versus Cobalt-Chromium Everolimus-Eluting Stent in De Novo Native Coronary Lesions: The Final 5-Year Results of the TARGET I Randomized Controlled Trial

Bo Xu - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

sirolimus

Bare Metal Stent, Durable Polymer Drug Eluting Stent, or Biodegradable Polymer Drug Eluting Stent in Patients with Diabetes Mellitus - A Mixed Treatment Comparison Analysis of 63,940 Patient-Years of Follow-up from Randomized Trials

Bora Toklu - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Venous thrombosis

N/A

Two-year outcomes after revascularization with a biodegradable polymer ultra-thin strut sirolimus eluting stent and a biodegradable polymer biolimus-eluting stent. From the SORT OUT VII trial

Lisette Okkels Jensen - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

sirolimus

Two Biodegradable Polymer-Based Sirolimus-Eluting Stents with Differing Elution and Absorption Kinetics: Two-Year Outcomes of the PANDA III Trial

Changdong Guan - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Venous thrombosis

sirolimus

Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention with Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration

Usman Baber - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Does metallic stent design influence acute and longterm clinical outcome in second generation Everolimus-Eluting stents? Results of a single-center, 2-phase all-comer stent registry

Suzanne Fateh-Moghadam - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Venous thrombosis

Promus Element

Long-term (1 year) Pathological Result of Everolimus-eluting versus Sirolimus-eluting and Bare Metal Stents

Hiroyoshi Mori - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Everolimus

Direct Implantation of Rapamycin-Eluting Stents with Bioresorbable Drug Carrier Technology Utilizing the Svelte Coronary Stent-on-a-Wire: 2-Year Follow-Up of the Randomized, Controlled DIRECT II Study

Stefan Verheye - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Rapacan

Paclitaxel - eluting stents vs Everolimus - eluting Coronary Stents in a Diabetic population: 2 Years Follow-up of TUXEDO-India Trial

Upendra Kaul - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Everolimus

Real-world experience of biolimus A9- and everolimus-eluting stents in all-comer Korean registries: Patient-oriented and stent-related 3-year outcomes from the multicenter prospective Biolimus-Korea-3000 registry and Excellent-Prime registry

Ch Kim - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Umirolimus

Multi-Center, Randomized Evaluation of the Elixir DESyne Novolimus Eluting Coronary Stent System with Biodegradable Polymer Compared to a Zotarolimus-Eluting Coronary Stent System: Final 5-Year Results from the EXCELLA BD Study

Stefan Verheye - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

ZoMaxx

Comparison of Two Biodegradable Polymer-Based Sirolimus-Eluting Stents with Varying Elution and Absorption Kinetics in Acute Myocardial Infarction Patients: A Subgroup Analysis of PANDA III Trial

Changdong Guan - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Venous thrombosis

sirolimus

Efficacy and Safety of Biodegradable Polymer Everolimus-eluting stents versus Durable Polymer Biolimus-eluting stents: A direct comparison meta-analysis of 8,476 patients from randomized trials

Chirag Bavishi - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Everolimus

Impact of stent length on clinical outcomes following implantation of novel abluminal coated sirolimus eluting stent for long coronary lesions

Rashmit Pandya - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Venous thrombosis

sirolimus

The Influence of Diabetes Mellitus on Clinical Outcomes Following Implantation of a novel abluminal coated sirolimus eluting stent that enhances drug delivery through the delivery balloon: Insights from en-ABL e-Registry

Luca Testa - Transcatheter Cardiovascular Therapeutics (TCT) , 2016

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Venous thrombosis

sirolimus

Filters

7277 Abstracts